lonza 3 adc/media/files/japan/news... · dr. kristin koehler investor relations lonza group ltd tel...

Lonza Group Ltd│ Muenchensteinerstrasse 38 │CH-4002 Basel │Switzerland +41 61 316 81 11 │ www.lonza.com │ media@lonza.com

MEDIA RELEASE

Lonza

3 ADC

Lonza & Karen Fallen (Head of Mammalian and Microbial Development and

Manufacturing)

ADC 11 IND 5 3

ADC

Lonza & Thomas Rohrer (Head of Commercial Development Bioconjugates)

Lonza Group Ltd│ Muenchensteinerstrasse 38 │CH-4002 Basel │Switzerland +41 61 316 81 11 │ www.lonza.com │ media@lonza.com

2019 7 24 ( ) – Lonza

3 (ADC)

12

Lonza 3

ADC FDA

(CDMO)

2

Lonza

( )

2020 Ibex™Solutions

(HPAPI)

cGMP

Lonza

Lonza Healthcare Continuum™

Lonza & Lonza

Lonza 1897 2018 100

15,500 2018

Lonza Group Ltd│ Muenchensteinerstrasse 38 │CH-4002 Basel │Switzerland +41 61 316 81 11 │ www.lonza.com │ media@lonza.com

55 CORE EBITDA 15 www.lonza.com

Dr. Kristin Koehler

Investor Relations

Lonza Group Ltd

Tel +41 61 316 8782

kristin.koehler@lonza.com

Dr. Sanna Fowler

Head of External Communications

Lonza Group Ltd

Tel +41 61 316 8929

sanna.fowler@lonza.com

Lonza

SGX-ST Lonza SGXST

SGXST 217 751

Lonza Lonza

Lonza

Lonza Ltd. 2019 7 24

Lonza Expands Bioconjugation Facility and Announces Approval of Third Commercial ADC